Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiniksa Pharmaceuticals International (KNSA) Retained Earnings (2021 - 2025)

Kiniksa Pharmaceuticals International's Retained Earnings history spans 5 years, with the latest figure at -$462.1 million for Q4 2025.

  • For Q4 2025, Retained Earnings rose 11.32% year-over-year to -$462.1 million; the TTM value through Dec 2025 reached -$462.1 million, up 11.32%, while the annual FY2025 figure was -$462.1 million, 11.32% up from the prior year.
  • Retained Earnings reached -$462.1 million in Q4 2025 per KNSA's latest filing, up from -$476.3 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $55000.0 in Q1 2023 to a low of -$700.6 million in Q1 2022.
  • Average Retained Earnings over 5 years is -$278.0 million, with a median of -$231.2 million recorded in 2025.
  • Peak YoY movement for Retained Earnings: crashed 3336123.81% in 2022, then surged 114.44% in 2023.
  • A 5-year view of Retained Earnings shows it stood at -$675.4 million in 2021, then skyrocketed by 100.01% to $44000.0 in 2022, then plummeted by 1086350.0% to -$478.0 million in 2023, then fell by 9.04% to -$521.1 million in 2024, then increased by 11.32% to -$462.1 million in 2025.
  • Per Business Quant, the three most recent readings for KNSA's Retained Earnings are -$462.1 million (Q4 2025), -$476.3 million (Q3 2025), and -$53000.0 (Q2 2025).